Preoperative postbiotic (butyrate) given before colorectal cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants with localized colorectal adenocarcinoma scheduled for elective resection will be assigned to one of two groups to receive either 900 mg of oral butyrate daily or a matching placebo for seven days prior to surgery. The study plans to enroll 164 participants over about two years at A.C. Camargo Cancer Center and will compare postoperative complication rates between the two groups. The rationale is based on evidence that microbially derived metabolites such as short-chain fatty acids can modulate immunity and support intestinal barrier integrity. The trial aims to determine whether short-term preoperative supplementation can translate these effects into fewer surgical complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals diagnosed with malignant neoplasm of the large intestine, specifically adenocarcinoma.
* Patients over 18 years of age, of both sexes.
* Patients who agree to participate in the study and sign the informed consent form.

Exclusion Criteria:

* Emergency or urgent surgeries.
* Cytoreductive surgeries involving intraoperative intraperitoneal chemotherapy.
* Extended surgeries for the treatment of recurrent tumors.

Where it's running

• A.C.Camargo Cancer Center
  São Paulo, São Paulo, Brazil Recruiting

Study contacts

• Principal investigator: Samuel A Junior, MD, PhD — A.C.Camargo Cancer Center
• Study coordinator: Samuel A Junior, MD, PhD
• Email: samuel.aguiar@accamargo.org.br
• Phone: +5511 2189-5020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Longer antibiotic prophylaxis after head and neck cancer surgery

  This trial tests whether giving antibiotics for 7 days after major mouth and throat cancer surgery reduces wound infections compared with the standard 24-hour course.

  Recruiting Phase 3 AC Camargo Cancer Center · São Paulo, São Paulo · NCT07851857

• Early anti-PD1 therapy before surgery in high-risk stage II melanoma

  This study looks at real-world patients with high-risk stage II melanoma to see if starting anti-PD1 therapy before surgery changes outcomes compared with the usual timing.

  Recruiting AC Camargo Cancer Center · São Paulo, São Paulo · NCT07680699

• Surgical gloves to prevent hand neuropathy from oxaliplatin

  This trial will test whether wearing surgical gloves during oxaliplatin chemotherapy can prevent hand numbness and pain in adults with colon cancer.

  Recruiting AC Camargo Cancer Center · São Paulo, São Paulo · NCT07285356

• Real-world belzutifan outcomes and pharmacogenetics in von Hippel-Lindau syndrome

  This study will test belzutifan in people aged 14 and older with VHL syndrome to see how well it controls VHL-associated tumors, what side effects occur, and how genetic factors affect response.

  Recruiting Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo · NCT07167329

• Modulating gut bacteria with antibiotics for rectal cancer treatment

  This study is testing if using an antibiotic to change gut bacteria can help people with advanced rectal cancer respond better to radiation treatment.

  Recruiting Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo · NCT06793137

• Comparing two doses of Everolimus for treating neuroendocrine tumors

  This study is testing whether a lower dose of Everolimus can effectively treat patients with advanced neuroendocrine tumors while causing fewer side effects compared to a higher dose.

  Recruiting at 2 sites Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo and 1 other locations · NCT06472388

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.